Morgan Stanley cuts Alnylam price target to $240 from $300, keeps Equal-Weight
Morgan Stanley kept Alnylam at Equal-Weight and cut its price target to $240 from $300, a 20% reduction, citing Benzinga data via TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley kept its Equal-Weight rating on Alnylam Pharmaceuticals but lowered its price target by 20%, to $240 from $300, according to TradingView. The report, based on Benzinga data, says the new target implies upside of 37.9% from the October 29 close of $174.
Across the five most recent analyst notes over the past 30 days, price targets for the company range from $220 to $320, showing that analysts hold differing views on the stock.
why it matters
A single brokerage revising its target affects one company rather than the wider market. Such changes help investors gauge where Wall Street expectations sit for the biomedical name, but they rarely move major indexes on their own.
tags
instruments
sources
- Morgan Stanley maintains Alnylam Pharmaceuticals at Equal-Weight, lowers price target to $240 from $300 — TradingView, 30 October 2026 at 17:37 UTC
- Morgan Stanley maintains Caterpillar at Equal-Weight, lowers price target to $675 from $915 — TradingView, 30 October 2026 at 17:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗